Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: Incidence, risk factors and therapeutic options

Hematological Oncology

Volumn 27, Issue 2, 2009, Pages 61-70

  Ferreri, Andrés J M ^a   Assanelli, Andrea ^a   Crocchiolo, Roberto ^a   Ciceri, Fabio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Aggressive lymphoma; Central nervous system; CNS prophylaxis; Lymphomatous meningitis; Risk factors

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; IDARUBICIN; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; LIPOSOME; MELPHALAN; METHOTREXATE; NITROSOUREA; PREDNISONE; PROCARBAZINE; RITUXIMAB; THIOTEPA; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BRAIN LYMPHOMA; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID CYTOLOGY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DOSAGE SCHEDULE COMPARISON; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HYPERTENSION; IMMUNOCOMPROMISED PATIENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LIPOSOMAL DELIVERY; MORBIDITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROIMAGING; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; RECURRENCE RISK; REVIEW; RISK FACTOR; SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA; T CELL LYMPHOMA; TACHYPNEA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBROSPINAL FLUID; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; INJECTIONS, SPINAL; LYMPHOMA; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 66949131767     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.881     Document Type: Review

References (60)

1. Ferreri AJ, DeAngelis LM. Central nervous system lymphoma. Lymphoma: Pathology, Diagnosis and Treatment 2007; 14: 200-214.
2. Bollen EL, Brouwer RE, Hamers S, et al. Central nervous system relpase in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 1997; 54: 854-859.
3. van Biesen K, Hac S, Murphy S, et al. Risk factors, treatment and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91: 1178-1184.
4. Doolittle ND, Abrey LE, Shenkier TN, et al. Brain parenchyma involvement as isolated central nervous system (CNS) relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 2008; 111: 1085-1093.
5. Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relpase in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000; 11: 685-690.
6. Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade non-Hodgkin's lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18: 149-157.
7. Hollender A, Kvaloy S, Nome D, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002; 13: 1099-1107.
8. Spectre G, Gural A, Amir G, et al. Central nervous system involvement in indolent lymphomas. Ann Oncol 2005; 16: 450-454.
9. Anselmo AP, Proia A, Cartoni C, et al. Meningeal localization in a patient with Hodgkin's disease. Description of a case and review of the literature. Ann Oncol 1996; 7: 1071-1075.
10. Gerstner ER, Abrey LE, Schiff D, et al. CNS Hodgkin lymphoma. Blood 2008; 112: 1658-1661.
11. Ferreri AJ, Dognini GP, Campo E, et al. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica 2007; 92: 486-492.
12. Ferrer A, Bosch F, Villamor N, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19(1): 135-141.
13. Herman TS, Hammond TS, Jones SE, et al. Involvement of the central nervous system by non-Hodgkin's lymphoma: the southwest Oncology Group experience. Cancer 1979; 43: 390-397.
14. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266-272.
15. Bokstein F, Lossos A, et al. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002; 43: 587-593.
16. Johnson GJ, Oken MM, et al. Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: is prophylaxis indicated? Lancet 1984; 2: 685-687.
17. MacKintosh FR, Colby TV, Podolsky WJ, et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 1982; 49: 586-595.
18. Skarin AT, Canello GP, Rosenthal DS, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (MBACOD). J Clin Oncol 1983; 1: 91-98.
19. van Dongen JJ, Wolvers Tettero IL, et al. Analysis of immunoglobulin and T-cell receptor genes. Part 1: basic and technical aspects. Clin Chim Acta 1991; 198: 1-91.
20. Gleissner B, Siehl J, et al. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002; 58: 390-396.
21. Yoshida S, Morii K, et al. Characteristic features of malignant lymphoma with central nervous system involvement. Surg Neurol 2000; 53: 163-167.
22. Teshima T, Akashi K, Shibuya T, et al. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer 1990; 65: 327-332.
23. Glass JP, Melamed M, et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979; 29: 1369-1375.
24. Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105: 496-502.
25. Perez-Soler R, Smith TL, et al. Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. Cancer 1986; 57: 971-977.
26. Montserrat E, Bosch F, Lopez Giullermo A, et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996; 14: 941-944.
27. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large B-cell lymphoma: influence of Rituximab. Ann Oncol 2004; 15: 129-133.
28. van Biesen K, Ha CS, Murphy S, et al. Risk factors, treatment and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 4: 1178-1184.
29. Björkholm M, Hagberg H, Holte H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 2007; 18: 1085-1089.
30. Cortes J, O'Brien S, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous systemprophylaxis in different risk group of adult acute lymphoblastic leukemia. Blood 1995; 86: 2091-2097.
31. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-4289.
32. Schmitz N, Boehme V, Zeynalova S, et al. CNS recurrence in aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without Rituximab: an anlysis of CNS events in elderly patients treated in the ricover-60 trial of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Haematologica 2008; abstract book 398: 158.
33. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
34. Bos GM, van Putten WL, van der Holt B, et al. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 1998; 9: 191-194.
35. Recht L, Straus DJ, et al. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med 1988; 84: 425-435.
36. Bollen EL, Brouwer RE, Hamers S, et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 1997; 54: 854-859.
37. Hollender A, Kvaloy S, Nome D, et al. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 2000; 36: 1762-1768.
38. Thyss A, Milano G, Deville S, et al. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur J Cancer Clin Oncol 1987; 23: 843-847.
39. Milano G, Thyss A, Serre Debeauvais F, et al. CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group. Eur J Cancer 1990; 26: 492-495.
40. Millot F, Rubie H, et al. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate. Leuk Lymphoma 1994; 14: 141-144.
41. Ferreri AJ, Dell'Oro S, Foppoli M, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 2006; 66: 1435-1438.
42. Ferreri AJ, Foppoli M, et al. Randomized phase II trialon primary chemotherapy (CHT) with high-dose Methotrexate (MTX) alone or associated with high-dose Cytarabine (araC) for patients with primary CNS lymphoma (PCNSL) International Conference on Malignant Lymphoma, Lugano, abstract 2008.
43. Kim S, Khatibi S, Howell SB, et al. Prolongation of drug action in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res 1993; 53: 1596-1598.
44. Kim S, Chatelut E, Kim JC, et al. Extended CSF Cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 1993; 11: 2186-2193.
45. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17: 3110-3116.
46. Rubenstein JL, Combs D, Rosemberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101: 466-468.
47. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25: 1350-1356.
48. Williams CD, Pearce R, Taghipour G, et al. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome - a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 1994; 12: 2415-2422.
49. Alvarnas JC, Negrin RS, Horning SJ, et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Bone Marrow Transplant 2000; 6: 352-358.
50. van Biesen K, Forman A, et al. Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol 1997; 8: 515-524.
51. Wiebe VJ, Smith BR, et al. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 1992; 13: 241-270.
52. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 15: 4151-4156.
53. Varadi G, Or R, Kapelushnik J, et al. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma 1999; 34: 185-190.
54. Lotze C, Schuler F, Kruger WH, et al. Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study. Neuro Oncol 2005; 7: 508-510.
55. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study. J Clin Oncol 2002; 20: 4643-4648.
56. Hottinger AF, DeAngelis LM, et al. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 2007; 69: 1178-1182.
57. Sierra Del Rio M, Benouaich-Amiel A, et al. Treatment of primary central nervous system lymphoma in the immunocompetent patient. Rev Neurol 2008; 164: 569-574.
58. Ben ArushMW, Elhasid R. Effects of radiotherapy on the growth of children with leukemia. Pediatr Endocrinol Rev 2008; 5: 785-788.
59. Uyttebroeck A, Suciu S, Laureys G, et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer 2008; 44: 840-846.
60. Bluhm EC, Ronckers C, Hayashi RJ, et al. Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2008; 111: 4014-4021.